Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy

Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).

Cannot have received: systemic anti-cancer therapy

Exception: within 4 weeks prior to allocation

Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation.

Cannot have received: radiotherapy

Exception: within 2 weeks of start of study intervention; 1-week washout permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease

Has received prior radiotherapy within 2 weeks of start of study intervention. Subject must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.